Health Care·Pharmaceuticals·$119.9B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.83 | N/A | +0.11% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $1.83 | N/A | +0.11% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Overall, management conveyed a sense of cautious optimism regarding the company's performance. They emphasized the importance of their product pipeline and future growth potential.
Management expressed satisfaction with the EPS performance despite no revenue guidance.
They highlighted ongoing commitment to innovation and pipeline development.
Bristol Myers Squibb's earnings report shows a positive surprise in EPS, which likely contributed to the stock's 1.44% increase. The lack of revenue data leaves some uncertainty, but management's focus on innovation suggests they are positioning for future growth. Investors may view the EPS beat as a sign of resilience in a challenging market.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
ALPHABET INC Class A
Feb 1, 2022